AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32056776 — intervention group
Group type: COMPARATOR
Intervention: 8-session school-work programme (placebo group)
Number of subjects: 61
Study 32056776 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (WG)
Number of subjects: 61
Study 36190150 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseodensification drills (OD)
Number of subjects: 27
Study 36190150 — intervention group
Group type: COMPARATOR
Intervention: Piezoelectric implant site preparation (PISP)
Number of subjects: 27
Study 34185551 — intervention group
Group type: EXPERIMENTAL
Intervention: Donafenib (0.2 g orally twice daily)
Number of subjects: 668
Study 34185551 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (0.4 g orally twice daily)
Number of subjects: 668
Study 32389349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid VR during hydrotherapy
Number of subjects: 38
Study 32389349 — intervention group
Group type: COMPARATOR
Intervention: No hybrid VR during hydrotherapy
Number of subjects: 38
Study 35083533 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 18
Study 35083533 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 18
Study 33675088 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH carbohydrate consumption after glycogen-lowering cycling
Number of subjects: 11
Study 33675088 — intervention group
Group type: COMPARATOR
Intervention: LOW carbohydrate consumption after glycogen-lowering cycling
Number of subjects: 11
Study 33675088 — intervention group
Group type: COMPARATOR
Intervention: MIX carbohydrate consumption after glycogen-lowering cycling
Number of subjects: 11
Study 33675088 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH carbohydrate consumption
Number of subjects: 11
Study 33675088 — intervention group
Group type: COMPARATOR
Intervention: LOW carbohydrate consumption
Number of subjects: 11
Study 32728299 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F‐protein nanoparticle vaccine
Number of subjects: 4636
Study 32728299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4636
Study 35449064 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 vaccine messaging platforms (4‐min video, one‐page informational flyer, brief scripted face‐to‐face message delivered by an ED physician or nurse) during intervention weeks
Number of subjects: 1290
Study 35449064 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group does not receive messaging platforms)
Number of subjects: 1290
Study 32488456 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted self-help (TASH) intervention for parents (12-month duration, eight booklets plus up to 14 telephone consultations)
Number of subjects: 103
Study 32488456 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care only (waitlist control group)
Number of subjects: 103
Study 32511937 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sessions of computer-based working memory training
Number of subjects: 20
Study 32511937 — intervention group
Group type: COMPARATOR
Intervention: Attention training (control group)
Number of subjects: 20
Study 35329852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter plus oxytocin (12 hours with oxytocin added 6 hours after catheter insertion)
Number of subjects: 80
Study 35329852 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 80
Study 35329852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter plus oxytocin
Number of subjects: 80
Study 33145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 1600 IU/day
Number of subjects: 86
Study 33145984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 33932383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 33932383 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin
Number of subjects: 0
Study 33377958 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery pathway (17 evidence-based pre-, intra-, and postoperative care elements)
Number of subjects: 56
Study 33377958 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery pathway
Number of subjects: 56
Study 33377958 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 34389605 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target therapy
Number of subjects: 205
Study 34389605 — intervention group
Group type: COMPARATOR
Intervention: Not achieving remission at 6 months
Number of subjects: 205
Study 33559531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 15
Study 33559531 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15
Study 33559531 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 15
Study 32531762 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) plus lifestyle counseling (n = 25)
Number of subjects: 75
Study 32531762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity continuous training plus lifestyle counseling (TCT) (n = 27)
Number of subjects: 75
Study 32531762 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling alone (COU) (n = 23)
Number of subjects: 75
Study 35525712 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diagnostic strategy for pulmonary embolism (PE)
Number of subjects: 746
Study 35525712 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 746
Study 34590561 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-made Qingyuan Shenghua decoction (100 mL in the morning and 100 mL in the evening for 7 days)
Number of subjects: 80
Study 34590561 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same amount as the intervention group for 7 days)
Number of subjects: 80
Study 35241474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, Vitamin D, Vitamin K2, and Zinc
Number of subjects: 200
Study 35241474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RISP)
Number of subjects: 40
Study 32497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproex sodium (DVPX)
Number of subjects: 40
Study 32497602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization phase
Number of subjects: 40
Study 34982098 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES) - NOVA intracranial sirolimus-eluting stent system
Number of subjects: 263
Study 34982098 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS) - Apollo intracranial stent system
Number of subjects: 263
Study 33481914 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder for CRC screening invitation
Number of subjects: 0
Study 33481914 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder to complete and return FIT kit
Number of subjects: 0
Study 33481914 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS invitation for BC screening
Number of subjects: 0
Study 33481914 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation procedure
Number of subjects: 0
Study 32131802 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 0
Study 32131802 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35698100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy group (arm A)
Number of subjects: 244
Study 35698100 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm B)
Number of subjects: 244
Study 34808440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact moderate-intensity exercise program
Number of subjects: 124
Study 34808440 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 124
Study 32237884 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided exposure in CBT
Number of subjects: 197
Study 32856189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-seafood intervention
Number of subjects: 20
Study 32856189 — intervention group
Group type: COMPARATOR
Intervention: Non-seafood intervention
Number of subjects: 20
Study 32144133 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib + fulvestrant (G+F)
Number of subjects: 204
Study 32144133 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib + fulvestrant (E+F)
Number of subjects: 204
Study 32144133 — intervention group
Group type: COMPARATOR
Intervention: gefitinib
Number of subjects: 204
Study 32144133 — intervention group
Group type: COMPARATOR
Intervention: erlotinib
Number of subjects: 204
Study 35842107 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased n-3 EPA + DHA with low n-6 LA (H3L6)
Number of subjects: 122
Study 35842107 — intervention group
Group type: COMPARATOR
Intervention: Usual US dietary content of n-3 and n-6 fatty acids (Control)
Number of subjects: 122
Study 34138788 — intervention group
Group type: COMPARATOR
Intervention: ACLR
Number of subjects: 120
Study 34138788 — intervention group
Group type: EXPERIMENTAL
Intervention: ALSA
Number of subjects: 120
Study 32294318 — intervention group
Group type: EXPERIMENTAL
Intervention: No Appointment but Reminder
Number of subjects: 651
Study 32294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment & Reminder
Number of subjects: 651
Study 32294318 — intervention group
Group type: COMPARATOR
Intervention: No Appointment & No Reminder (control arm)
Number of subjects: 651
Study 35171190 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla seed oil (PO)
Number of subjects: 49
Study 35171190 — intervention group
Group type: COMPARATOR
Intervention: Perilla seed oil with nobiletin-rich ponkan powder (POPP)
Number of subjects: 49
Study 35171190 — intervention group
Group type: EXPERIMENTAL
Intervention: POPP
Number of subjects: 49
Study 34163193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufang Zhenzhu Tiaozhi capsule (FTZ) with basic treatment
Number of subjects: 160
Study 34163193 — intervention group
Group type: COMPARATOR
Intervention: Placebo with basic treatment
Number of subjects: 160
Study 33012443 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 24
Study 33012443 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 36053020 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAUMACEM V+ Injectable Bone Cement augmentation
Number of subjects: 0
Study 36053020 — intervention group
Group type: COMPARATOR
Intervention: No augmentation
Number of subjects: 0
Study 33223395 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN medication prescribed
Number of subjects: 242
Study 33223395 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN medication administered
Number of subjects: 242
Study 33223395 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN medication administration
Number of subjects: 242
Study 33223395 — intervention group
Group type: COMPARATOR
Intervention: Overall PRN prescribing and administration
Number of subjects: 242
Study 32237290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (50 or 70 mg)
Number of subjects: 319
Study 32237290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 36121045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Embolic Protection (CEP) during TAVR
Number of subjects: 3000
Study 36121045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CEP) during TAVR
Number of subjects: 3000
Study 34221018 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste® (bleaching and MI Paste®)
Number of subjects: 45
Study 34221018 — intervention group
Group type: COMPARATOR
Intervention: Control (only bleaching)
Number of subjects: 45
Study 34221018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MI Paste® and control)
Number of subjects: 45
Study 32660716 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 60
Study 34379589 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed quantization system for heatmap regression
Number of subjects: 0
Study 34379589 — intervention group
Group type: COMPARATOR
Intervention: High-resolution heatmaps (previous methods)
Number of subjects: 0
Study 35776843 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Number of subjects: 30
Study 35776843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 616381975 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz for 1200 pulses with two boosters)
Number of subjects: 10
Study 616381975 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (disconnected coil)
Number of subjects: 10
Study 34291992 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted mindfulness-based smoking cessation intervention with contingency management (SMI-CM)
Number of subjects: 49
Study 34291992 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard treatment (EST)
Number of subjects: 49
Study 34291992 — intervention group
Group type: EXPERIMENTAL
Intervention: SMI-CM
Number of subjects: 49
Study 34931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low psychosocial burden group (n=231)
Number of subjects: 287
Study 34931480 — intervention group
Group type: COMPARATOR
Intervention: High psychosocial burden group (n=56)
Number of subjects: 287
Study 34931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline psychosocial variables (SF-36, IPQ-R, UCL)
Number of subjects: 287
Study 34931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 16 psychosocial variables (SF-36, IPQ-R)
Number of subjects: 287
Study 34931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal relationships between psychosocial wellbeing and DAS28-CRP
Number of subjects: 287
Study 32860737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Number of subjects: 20
Study 32860737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32483139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 mcg/kg given 2 minutes before intubation
Number of subjects: 145
Study 32483139 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 mcg/kg given 1 minute before intubation
Number of subjects: 145
Study 32483139 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 mcg/kg given 3 minutes before intubation
Number of subjects: 145
Study 36396519 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg for 14 days once daily
Number of subjects: 472
Study 36396519 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no thromboprophylaxis)
Number of subjects: 472
Study 33032917 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed about the activity tracker
Number of subjects: 235
Study 33032917 — intervention group
Group type: COMPARATOR
Intervention: Blinded to the purpose of the activity tracker
Number of subjects: 235
Study 35667914 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Ad26.COV2.S (5 × 10^10 viral particles)
Number of subjects: 73
Study 35667914 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 10^10 vp 2-month booster dose
Number of subjects: 73
Study 35667914 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month booster (5 × 10^10 vp)
Number of subjects: 73
Study 35667914 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month booster (1.25 × 10^10 vp)
Number of subjects: 73
Study 35667914 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses
Number of subjects: 73
Study 32514590 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal evaporative intra-arrest cooling initiated by emergency medical services (early cooling)
Number of subjects: 300
Study 32514590 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal evaporative intra-arrest cooling initiated by emergency medical services (early cooling) in patients with shockable rhythm
Number of subjects: 300
Study 32514590 — intervention group
Group type: COMPARATOR
Intervention: Cooling started after hospital arrival (control)
Number of subjects: 300
Study 32514590 — intervention group
Group type: COMPARATOR
Intervention: Cooling started after hospital arrival (control) in patients with shockable rhythm
Number of subjects: 300
Study 36568722 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia and ginger mixture (Memoral: 360 mg Boswellia and 36 mg ginger)
Number of subjects: 100
Study 36568722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35971135 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-GAP + Texting
Number of subjects: 0
Study 35971135 — intervention group
Group type: COMPARATOR
Intervention: Texting only
Number of subjects: 0
Study 32233251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (0.5 g diluted in 20 ml normal saline)
Number of subjects: 60
Study 32233251 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (10 ml)
Number of subjects: 60
Study 32829540 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide mixed with dexamethasone
Number of subjects: 120
Study 32829540 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste
Number of subjects: 120
Study 32829540 — intervention group
Group type: COMPARATOR
Intervention: Cotton pellet (placebo)
Number of subjects: 120
Study 34693748 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Health Team arm
Number of subjects: 0
Study 34693748 — intervention group
Group type: COMPARATOR
Intervention: Primary Care Group Education arm
Number of subjects: 0
Study 32545100 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy intervention
Number of subjects: 18
Study 35285940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI in African ancestry patients
Number of subjects: 2854
Study 35285940 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI ≥40) in African ancestry patients
Number of subjects: 2854
Study 35285940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI in estrogen receptor-positive (ER+) African ancestry patients
Number of subjects: 2854
Study 35285940 — intervention group
Group type: COMPARATOR
Intervention: Higher BMI in European ancestry patients
Number of subjects: 2854
Study 34310694 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting an arterial partial pressure of oxygen of 8 kPa
Number of subjects: 780
Study 34310694 — intervention group
Group type: COMPARATOR
Intervention: Targeting an arterial partial pressure of oxygen of 12 kPa
Number of subjects: 780
Study 32586268 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + green tea
Number of subjects: 30
Study 32586268 — intervention group
Group type: COMPARATOR
Intervention: HIIT + placebo
Number of subjects: 30
Study 32586268 — intervention group
Group type: COMPARATOR
Intervention: green tea
Number of subjects: 30
Study 34728062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day
Number of subjects: 198
Study 34728062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 34019711 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-042 (5, 7.5, 10, 20, 20 (evening), 40 μg)
Number of subjects: 0
Study 34019711 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-042 (5-40 μg)
Number of subjects: 0
Study 34019711 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-042
Number of subjects: 0
Study 34019711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32456653 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUST4RD approach for identifying uncertainties in evidence generation
Number of subjects: 0
Study 32456653 — intervention group
Group type: EXPERIMENTAL
Intervention: Real World Evidence (RWE)
Number of subjects: 0
Study 34791356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychoeducation (CBE)
Number of subjects: 36
Study 34791356 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 36
Study 34293413 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent chair-based exercise intervention (16 weeks, twice a week, 60 min)
Number of subjects: 52
Study 34293413 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 52
Study 32769595 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injection (ESI)
Number of subjects: 266
Study 34085136 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (Equistasi®)
Number of subjects: 24
Study 34085136 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 24
Study 33919500 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills
Number of subjects: 1745
Study 33919500 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in life skills
Number of subjects: 1745
Study 35986353 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Tribulus terrestris supplement twice daily for 2 weeks
Number of subjects: 34
Study 35986353 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules twice daily for 2 weeks
Number of subjects: 34
Study 34288094 — intervention group
Group type: EXPERIMENTAL
Intervention: LiRIS 400 mg
Number of subjects: 190
Study 34288094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 33041071 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG‐99mTc‐nanocolloid (fluorescence imaging group)
Number of subjects: 48
Study 33041071 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐nanocolloid with blue dye (standard group)
Number of subjects: 48
Study 32515119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 10 mg/kg
Number of subjects: 91
Study 32515119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 33070045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL)
Number of subjects: 77
Study 33070045 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL)
Number of subjects: 77
Study 34864678 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory Training (OT), performed twice a day for 4 months
Number of subjects: 38
Study 34864678 — intervention group
Group type: COMPARATOR
Intervention: Control training condition, performed twice a day for 4 months
Number of subjects: 38
Study 32988369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 0